HIV PrEP Curbside Consults: Tackling Challenging Scenarios in Everyday Practice
Tracking # 20-1314908
Free
Course overview
Pre-exposure prophylaxis (PrEP) is a key strategy for preventing HIV, but identifying individuals at risk remains challenging due to stigma, discrimination, and lack of trust between patients and clinicians. Updated guidelines from The Centers for Disease Control and Prevention (CDC) recommend informing all sexually active individuals about PrEP and taking a brief, targeted sexual history to assess risk. Providers should offer PrEP to those at substantial risk, including individuals with partners of unknown or positive HIV status, recent bacterial sexually transmitted infections, or injection drug use. The available options for PrEP include oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), oral FTC/tenofovir alafenamide (TAF), and injectable cabotegravir. Expanding PrEP uptake requires clinician education; improved access; as well as addressing barriers such as stigma, cost, and patient-provider communication. In this Curbside Consult series, expert faculty discuss evidence-based HIV risk assessment, guideline-based PrEP selection, and patient-centered strategies for choosing the most appropriate PrEP.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
Upon successful completion of this educational activity, participants should be better able to:
- Employ evidence-based approaches to assess patient risk for acquiring HIV infection.
- Use the latest guideline recommendations to identify patients who may benefit from HIV PrEP.
- Select HIV PrEP based on the most recent clinical evidence, access, and patient preferences.
- Incorporate multidisciplinary/interprofessional strategies, shared decision-making, and other patient-centered strategies to improve adherence and follow-up.